English Name: rivaroxaban

CAS No.: 366789-02-8

Molecular formula: c19h18cln3o5s

Molecular weight: 435.88

EINECS No.: 685-132-2

Effects: rivaroxaban is the first oral factor Xa inhibitor in the world. It can selectively and competitively inhibit free and bound factor Xa and prothrombin activity, prolong activated partial thromboplastin time plate (PT) and prothrombin time (APTT) in a dose-dependent manner, thus prolonging coagulation time and reducing thrombin formation. It has the characteristics of high bioavailability, wide treatment spectrum, stable dose effect relationship, convenient oral administration and low bleeding risk. Rivaroxaban is also a drug for the prevention and treatment of venous thrombosis. Clinically, it is mainly used to prevent the formation of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement. It can also be used to prevent stroke and non central nervous system embolism in patients with nonvalvular atrial fibrillation and reduce the risk of recurrence of coronary syndrome.